You can buy or sell AVEO and other stocks, options, ETFs, and crypto commission-free!
AVEO Pharmaceuticals, Inc. Common Stock, also called AVEO Pharmaceuticals, is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Read More Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Markets InsiderMar 21
EQUITY ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors with Over $100K in Losses of Important Deadline in Securities Class Action Lawsuit - AVEO
NEW YORK, March 21, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc.
Guru FocusMar 21
DEADLINE NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. – AVEO
NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of AVEO Pharmaceuticals, Inc.
Associated PressMar 15
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. LOS ANGELES, March 1...
-$0.06 per share
-$0.03 per share